Navigation Links
Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
Date:12/1/2009

TEMECULA, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Patient Safety Technologies, Inc. (OTC Bulletin Board: PSTX) announced today that it has appointed Marc L. Rose, CPA(PA), to the position of Chief Financial Officer, Treasurer and Corporate Secretary, replacing Mary M. Lay, who has been acting CFO since 2008. Prior to joining Patient Safety Technologies, Inc., Mr. Rose was Vice President Finance, Chief Financial Officer, Treasurer and Corporate Secretary of Protalex, Inc., a publicly traded biotechnology company. In addition to his experience at Protalex, Mr. Rose was the Chief Financial Officer at DentalEZ Group, a privately held manufacturer. Mr. Rose has also served as a Practice Manager for Oracle Consulting Services, a Controller with Waste Management, Inc. and an Auditor with Ernst & Young. Mr. Rose is a Certified Public Accountant in PA and received his BS in Accounting/Finance from Drexel University.

"Marc is a valuable addition to the Patient Safety Management team," said Steven H. Kane, President and Chief Executive Officer, "His thorough knowledge of public company reporting, systems implementation and operations will help PSTX continue to improve its financial infrastructure. This is a critical component in helping PSTX reach its goal of establishing its technology as the industry standard of care." Mr. Rose added, "I'm excited about the opportunity and I look forward to contributing to the success of the company."

About Patient Safety Technologies, Inc. and SurgiCount Medical, Inc.

Patient Safety Technologies, Inc., through its wholly owned operating subsidiary SurgiCount Medical, Inc., provides the Safety-Sponge((TM)) System, a system designed to improve the standard of patient care and reduce healthcare costs by preventing the occurrence of surgical sponges and other foreign objects from being left inside patients after surgery. RFOs are among one of the most common surgical errors.


'/>"/>
SOURCE Patient Safety Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "North America Mammography Market ... 2019)"  report to their offering. ... is a detailed type of imaging that ... breasts. A mammography exam, called a mammogram, ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... third quarter 2011 financial results after the market closes on ... webcast will be held on Thursday, November 3, 2011, at ... To participate in the call, please dial 877-303-1298 (for U.S. ...
... 2011 IDenta Corp. (OTC: IDTA) CEO Yaacov Shoham today ... are succeeding in making sales in many new markets, including ... We have received an order for 2000 detectors from the ... In the past several months we have ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2
(Date:5/27/2015)... May 27, 2015 The BBB Code ... service practices that enhance customer trust and confidence in ... for Trust, eight principles that summarize important elements of ... represents standards for business accreditation by BBB. Businesses based ... standards and complete application procedures will be accredited by ...
(Date:5/27/2015)... 27, 2015 Hundreds of Risperdal ... of individuals who allegedly suffered gynecomastia (male breast ... of the antipsychotic drug continue to move forward ... Pennsylvania’s Philadelphia Court of Common Pleas. According to ... bellwether trial program, as the third trial involving ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Dr. Omar ... based in Stamford, CT has been selected as part ... first physicians nationwide (and the only physician in Connecticut) ... which allows for the removal of submental fat (double ... no recovery time, no surgery and minimal risks. Dr. ...
(Date:5/27/2015)... May 27, 2015 Black Book ... satisfaction surveys in the multiple services and software ... determine the highest ranked Electronic Health and Medical ... a special research focus on implemented EHR users, ... software vendors with the highest scores in client ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4
... LIONVILLE, Pa., Oct. 18 West Pharmaceutical,Services, Inc. ... to Pfizer,Inc.,s announcement that it has decided to ... marketing rights to the,Company,s customer, Nektar Therapeutics, Inc. ... that produce the Exubera inhalation device for Nektar. ...
... poorest prognosis -- those with a type of deadly tumor ... a drug that chokes off a tumors blood supply. ... Preston Robert Tisch Brain Tumor Center, a combination of bevacizumab ... agent, may increase the amount of time GBM patients can ...
... Patients Released From Hospital Within 24-48 Hours, ... Texas man is,the first brain tumor patient in ... that removes pituitary tumors without making incisions,in the ... and the,Director of the Trinity Mother Frances Neuroscience ...
... override SCHIP veto, WASHINGTON, Oct. 18 The ... a sad day when America,s children can,t depend on ... after their most basic needs. It,s,a sad day when ... citizens., "The failure of the House of Representatives ...
... students today said they were deeply saddened that Congress ... legislation to re-authorize the State Childrens Health Insurance Program ... another bill that provides comparable levels of funding and ... go far enough, said David C. Dale, MD, FACP, ...
... is a statement from Greg,Tarpinian, Executive Director of ... President Bush,s veto of SCHIP. "Change to ... and,some courageous Republicans to override President Bush,s veto ... whose parents cannot,afford it. "In failing to ...
Cached Medicine News:Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2Health News:Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure 2Health News:Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure 3Health News:Congressional failure to override SCHIP veto 'saddens' physicians 2
... Mumps IgG ELISA test system is intended ... antibody in human serum. When performed according ... test, together with other clinical information, may ... and/or aid in the diagnosis of Mumps ...
... IgG Enzyme-linked Immunosorbent Assay (ELISA) is intended ... IgG antibody to Mumps virus in human ... for the determination of immune status. Paired ... to demonstrate seroconversion or a significant rise ...
... the TEG analyzer and the TEG analytical software, ... formation and dissolution of the clot, showing the ... TEG analyzer is the only hemostasis analyzer available ... proven model developed by Prof. Helmut Hartert in ...
... BareWire technology, the wire crosses the lesion ... catheter. All other actions, including filter placement ... then occur over the wire., ,Emboshield is ... off during a carotid stenting procedure, and ...
Medicine Products: